Progress in application of high temperature superconductor in tokamak magnets

It has long been known that high temperature superconductors (HTS) could have an important role to play in the future of tokamak fusion research. Here we report on first results of the use of HTS in a tokamak magnet and on the progress in design and construction of the first fully-HTS tokamak.     

Morphology,structure, and chemistry of nanoclusters in a mechanically alloyed nanostructured ferritic steel

Nanostructured ferritic steels have excellent elevated temperature strengths, creep resistances, and radiation tolerances due to the presence of a high density of Ti–Y–O-enriched nanoclusters. The compositions, morphologies, and structures of the smallest of these nanoclusters with maximum dimensions of ~2–4 nm were investigated in alloy 14YWT by high-resolution scanning transmission electron microscopy and atom probe tomography. Nanoclusters are found to be coherent with truncated rhombic dodecahedron morphologies defined by the {100} and {110} planes in the Fe matrix. Particles have compositions rich in Ti, O, Y, and Cr that are inconsistent with known oxide structures. The smallest nanoclusters appear to lack an identifiable crystal structure. Both nano-diffraction and focal series imaging through the sample thickness suggest that they are amorphous.     

Microenvironment of the high affinity ATP-binding site of Na+/K+-ATPase is slightly acidic

Fluorescein-5'-isothiocyanate (FITC) was used to study the high-affinity ATP-binding site of Na+/K+-ATPase. The molar ratio of specifically bound FITC per alpha-subunit of Na+/K+-ATPase was found to be 0.5 as followed from pretreatment experiments with another specific E1ATP-inhibitor Cr(H2O)4AdoPP[CH2]P. This indicated an existence of one high affinity ATP-binding site (E1ATP-binding site) in the native (alphabeta)2-diprotomer of Na+/K+-ATPase. Fluorescence dual-excitation ratio of specifically bound FITC revealed that at external pH 7.5, the pH value inside the E1ATP-binding site is 6.95 +/- 0.18. In addition, FITC fluorescence quenching by anti-fluorescein and by iodide choline indicated the limited access of water into the small pocket of the E1ATP-binding site.     

The viable motheaten (mev) mouse--a new model for arthritis

Homozygous mev mice are first identified at the age of 3-4 days by focal depigmentation of the skin, followed by patchy absence of hair and by necrotic lesions on paws, tail and ears. Of particular interest are the inflammatory reactions in the paws of these animals which consist mainly of polymorphonuclear and mononuclear cell infiltration in the subcutaneous tissue extending to the periosteum and joint, resulting in focal destructive arthritis and osteomylitis. These lesions are to some extent reminiscent of an acute form of rheumatoid-like arthritis. Since mev mice are sterile, a limited number of symptomatic offspring can be obtained by cross-breeding their heterozygous siblings which are phenotypically not distinguishable from mice lacking this mutation. In order to produce a sufficient number of diseased animals for performing pharmacological studies, we have established a model by transferring this disease in lethally irradiated, 8- to 10-week-old syngeneic mice which were grafted with mev spleen cells. Such reconstituted recipients develop first inflammatory symptoms of the paws 2 to 3 weeks after cell transfer. The arthritic inflammation finally affects all paws and toes by 30 to 50 days. This procedure increased the number of mev-like mice expressing arthritis, allowing assessment of the effects of standard reference drugs used in the therapy of rheumatoid arthritis (RA). The immunosuppressants cyclosporin and rapamycin and the steroid dexamethasone at therapeutic concentrations exert a strong inhibitory effect on the development of arthritis in this novel model. In contrast, the non-steroidal anti-inflammatory drug phenylbutazone shows only a moderate effect. These results indicate the particular sensitivity of this model for efficacy of potentially new therapeutic but non-cytostatic compounds for clinical use.